Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GABRA1 | P14867 | 4/20 | 0.48 |
| ▸ | GABRB2 | P47870 | 4/20 | 0.48 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.42 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.40 |
| ▸ | HTR1A | P08908 | 1/20 | 0.40 |
| ▸ | SHBG | P04278 | 1/20 | 0.40 |
| ▸ | NOS3 | P29474 | 1/20 | 0.39 |
| ▸ | NOS2 | P35228 | 1/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.39 |
| ▸ | NLRP3 | Q96P20 | 1/20 | 0.38 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.37 |
| ▸ | SCN5A | Q14524 | 1/20 | 0.37 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.37 |
| ▸ | TP53 | P04637 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL169506 | 1.00 | GABRA1 (0.48) | GABRA1GABRB2CYP1A2CYP3A4CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL150658 | 0.98 | GABRA1 (0.46) | GABRA1GABRB2CYP1A2CYP3A4CYP2D6 | |
| Methylamine SCHEMBL27931104 | 0.98 | GABRA1 (0.46) | GABRA1GABRB2CYP1A2CYP3A4CYP2D6 | |
| Ammonia Solution, Strong SCHEMBL7055042 | 0.98 | GABRA1 (0.46) | GABRA1GABRB2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9488152 | 0.93 | SHBG (0.44) | GABRA1GABRB2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28536733 | 0.89 | GABRA1 (0.40) | GABRA1GABRB2CYP1A2CYP3A4CYP2D6 | |
| Formamide SCHEMBL27885905 | 0.89 | GABRA1 (0.40) | GABRA1GABRB2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL3642069 | 0.89 | GABRA1 (0.42) | GABRA1GABRB2CYP1A2CYP3A4CYP2D6 | |
| Diethylamine SCHEMBL6284503 | 0.89 | CYP1A2 (0.40) | GABRA1GABRB2CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL9839879 | 0.88 | TAAR1 (0.41) | GABRA1GABRB2CYP1A2CYP3A4CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7651603-B2 | Contacting hydrocarbonaceous feed at hydrocarbon converting conditions with catalyst comprising crystalline molecular sieve having STI topology and mole ratio of at least 15 of an oxide of a first tetravalent element to an oxide of a trivalent element, pentavalent element, a second tetravalent element | CHEVRON U.S.A. INC. (US) | 2010-01-26 | — | — | US | disclosed |
| US-7601255-B2 | Process for removal of residual catalyst components | CHEMTURA CORPORATION (US) | 2009-10-13 | — | — | US | disclosed |
| US-7396969-B2 | Process for preparing short chain alkyl aromatic compounds | MOBIL OIL CORPORATION (US) | 2008-07-08 | — | — | US | disclosed |
| US-20080053873-A1 | Process for removal of residual catalyst components | LANXESS SOLUTIONS US INC. | 2008-03-06 | — | — | US | disclosed |
| US-20070284284-A1 | Contacting hydrocarbonaceous feed at hydrocarbon converting conditions with catalyst comprising crystalline molecular sieve having STI topology and mole ratio of at least 15 of an oxide of a first tetravalent element to an oxide of a trivalent element, pentavalent element, a second tetravalent element | CHEVRON U.S.A. INC. | 2007-12-13 | — | — | US | disclosed |
| US-20050197517-A1 | Process for preparing short chain alkyl aromatic compounds | EXXONMOBIL OIL CORPORATION | 2005-09-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070284284-A1 | Contacting hydrocarbonaceous feed at hydrocarbon converting conditions with catalyst comprising crystalline molecular sieve having STI topology and mole ratio of at least 15 of an oxide of a first tetravalent element to an oxide of a trivalent element, pentavalent element, a second tetravalent element | SRP72, MUS81, SSU72 | GABRA1 2505/4885GABRB2 3339/4885CYP1A2 1499/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.